The European medicines regulator has started reviewing a submission from Japanese drugmaker Otsuka Pharmaceutical for its acute myeloid leukemia (AML) therapy A 22 August 2022
A regulatory submission from British firm Mundipharma, for the invasive candidiasis (IC) candidate rezafungin, has been accepted for review by the European Medi 22 August 2022
Lynparza has been approved in the EU as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer. 4 August 2022
AbbVie has announced that the European Commission has approved Rinvoq.an oral therapy for the treatment of active non-radiographic axial spondyloarthritis (nr-a 29 July 2022
RINVOQ (upadacitinib) has been approved by the European Commission for the treatment of adult patients with moderately to severely active ulcerative colitis who 26 July 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.